FindTrial
Sign In

To compare the efficacy of topical 0.1% Betamethasone valerate and fractional co2 laser with topical 0.1% Betamethasone valerate in treatment of Alopecia areata

A Comparitive study to assess efficacy of topical 0.1% betamethasone valerate versus fractional co2 laser with 0.1% topical betamethasone valerate in treatment of alopecia areata

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055395
Enrollment
80
Registered
2023-07-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L639- Alopecia areata, unspecified

Interventions

Intervention1: fractional co2 laser with 0.1% betamethasone valerate: Group B- patients with alopecia areata will be treated with fractional co2 laser (energy-30mJ, duration-0.6msec, single passe). T

Sponsors

Dr KVignesh kumar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient with alopecia areata patients will be divided into Group A & Group B. Each group comprising of 40 patients. 40 patients in Group A will be use topical 0.1% betamethasone alone 40 patients in Group B will treated with fractional co2 with topical 0.1% betamethasone. Maximum 6 sittings will be given at 2 weeks interval. Patient will receive no other therapies during study

Exclusion criteria

Exclusion criteria: Before starting the study Pregnant and lactating women. Women planning for pregnancy Children less than 14 years During Study If patient wants alternate treatment during the study. If patient wants to discontinue the treatment.

Design outcomes

Primary

MeasureTime frame
Hair regrowth in alopecia patches Timepoint: 24 weeks post study—

Secondary

MeasureTime frame
atrophy of skinTimepoint: 12 weeks post study—

Countries

India

Contacts

Public ContactDrKVignesh kumar

Chengalpattu Medical College and hospital

dermcliniccmch@gmail.com9994873182

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026